Rapport Therapeutics (NASDAQ:RAPP) Coverage Initiated at JMP Securities

Equities research analysts at JMP Securities started coverage on shares of Rapport Therapeutics (NASDAQ:RAPP) in a report issued on Tuesday,Benzinga reports. The brokerage set a “market outperform” rating and a $28.00 price target on the stock. JMP Securities’ price objective suggests a potential upside of 211.80% from the company’s current price.

Separately, Citizens Jmp began coverage on Rapport Therapeutics in a research report on Tuesday. They set a “mkt outperform” rating on the stock. Four analysts have rated the stock with a buy rating, According to MarketBeat, Rapport Therapeutics currently has an average rating of “Buy” and an average price target of $32.67.

Rapport Therapeutics Price Performance

NASDAQ:RAPP opened at $8.98 on Tuesday. The business’s 50-day moving average is $11.49 and its two-hundred day moving average is $17.27. The firm has a market capitalization of $327.73 million and a PE ratio of -0.65. Rapport Therapeutics has a 12 month low of $6.43 and a 12 month high of $29.74.

Insider Buying and Selling at Rapport Therapeutics

In other Rapport Therapeutics news, CFO Troy A. Ignelzi bought 9,900 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were purchased at an average price of $10.10 per share, with a total value of $99,990.00. Following the completion of the acquisition, the chief financial officer now directly owns 9,900 shares of the company’s stock, valued at approximately $99,990. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Wendy B. Young bought 6,000 shares of the stock in a transaction dated Wednesday, March 12th. The shares were bought at an average cost of $10.21 per share, with a total value of $61,260.00. Following the completion of the acquisition, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $61,260. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here.

Institutional Trading of Rapport Therapeutics

Several hedge funds have recently made changes to their positions in RAPP. BNP Paribas Financial Markets bought a new position in Rapport Therapeutics during the 3rd quarter worth $34,000. KLP Kapitalforvaltning AS bought a new position in shares of Rapport Therapeutics during the fourth quarter worth about $34,000. Deutsche Bank AG acquired a new stake in shares of Rapport Therapeutics in the 4th quarter worth about $41,000. New York State Common Retirement Fund bought a new stake in Rapport Therapeutics in the 4th quarter valued at about $62,000. Finally, Virtus ETF Advisers LLC acquired a new position in Rapport Therapeutics during the 4th quarter valued at about $66,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.